CoChat

The DOI matches its Crossref record.

Comparative Analgesia, Cardiovascular and Renal Effects of Celecoxib, Rofecoxib and Acetaminophen (Paracetamol)

Graham, Garry, Graham, Robert, Day, Richard · 2002 · Current Pharmaceutical Design

Abstract

Comparisons are made between the specific COX-2 inhibitors, celecoxib and rofecoxib, and acetaminophen. The specific COX-2 inhibitors are a significant advance in therapy because their anti-inflammatory, analgesic and antipyretic activities are associated with a high degree of gastrointestinal safety. Acetaminophen is often not considered to be a potent inhibitor of COX-2 but it is a potent inhibitor of prostaglandin synthesis in intact cells after stimulation by cytokines. Its weak activity on the pathway of prostanoid synthesis involving COX-1 is shown by its weak anti-platelet activity and good gastrointestinal safety. The specific COX-2 inhibitors and acetaminophen are analgesic after dental surgery, orthopedic surgery and in osteoarthritis although acetaminophen appears to be a slightly weaker agent. The apparent analgesic activity of both the COX-2 inhibitors and acetaminophen may, in part, be due to their anti-inflammatory properties. Both groups of drugs also decrease the urinary excretion of prostacyclin metabolites consistent with inhibition of the systemic and renal activity of the COX-2 system. During repeated dosage with the specific COX-2 inhibitors, the 24 hour urinary excretion of sodium is only inhibited for the first day of treatment while the excretion of sodium is still decreased over the first 3 hours after the individual doses. Therapeutic doses of the COX-2 inhibitors and overdoses of acetaminophen have been associated with the development of occasional cases of acute renal failure. Acetaminophen also may decrease the excretion of sodium and the reason for its greater renal safety at therapeutic doses is unclear. Myocardial infarction has also been attributed to the specific COX-2 inhibitors from meta-analysis of large scale clinical trials and examination of reports of adverse drug reactions although this is still a topic of considerable discussion. No such associations have been made with acetaminophen, possibly because it is a weak inhibitor of COX-1 in platelets.

Overview

Integrity signals

Registry

Crossref · 10.2174/1381612023394917

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 46

Metadata

Authors
Graham, G., Graham, R., & Day, R.
Affiliations
UNSW Sydney (AU)
Corresponding author
Day, Richard
Venue
Current Pharmaceutical Design
Published
2002-06-01
Volume
8
Issue
12
Pages
1063-1075
ISSN
1381-6128 (ISSN-L)
OpenAlex
W2126503814
Cited by
46
References
0
Citations by year
2026: 1 · 2023: 4 · 2022: 1 · 2021: 3 · 2019: 2 · 2017: 1 · 2016: 1 · 2015: 3 · 2014: 1 · 2013: 1 · 2012: 3
FWCI
3.43
Type
journal article
Language
en
Open access
closed
Locations
  • Current Pharmaceutical Design (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
Keywords
celecoxib, rofecoxib, paracetamol, COX-2 inhibitors, analgesia, cardiovascular effects, renal effects, acute kidney injury, sodium excretion, prostacyclin metabolites, myocardial infarction, anti-inflammatory activity, gastrointestinal safety, osteoarthritis
MeSH terms
Celecoxib, Acetaminophen, Analgesia, Cardiovascular System, Clinical Trials as Topic, Humans, Isoenzymes, Kidney, Lactones, Liver, Membrane Proteins, Osteoarthritis, Pain, Prostaglandin-Endoperoxide Synthases, Pyrazoles, Sulfonamides, Sulfones, Cyclooxygenase Inhibitors, Cyclooxygenase 1, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative Analgesia, Cardiovascular and Renal Effects of Celecoxib, Rofecoxib and Acetaminophen (Paracetamol). https://app.cochat.ai/papers/10.2174/1381612023394917
The paper
Graham, G., Graham, R., & Day, R. (2002). Comparative Analgesia, Cardiovascular and Renal Effects of Celecoxib, Rofecoxib and Acetaminophen (Paracetamol). Current Pharmaceutical Design. https://doi.org/10.2174/1381612023394917

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.